Search

Displaying results 4261 - 4270 of 6076 in total
  1. Drug

    AGA2115

    go.drugbank.com/drugs/DB17840
    Investigational

    Developed by Angitia Biopharmaceuticals, AGA2115 is being investigated for the treatment of osteogenesis imperfect.[L46646]

  2. Drug

    IMMU-114

    go.drugbank.com/drugs/DB18458
    Investigational

    IMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a CL2A linker.

  3. Drug

    ALT-P1

    go.drugbank.com/drugs/DB18485
    Investigational

    It is under investigation for the treatment of growth hormone deficiency.

  4. Drug

    Timbetasin

    go.drugbank.com/drugs/DB19119
    Investigational

    Timbetasin is under investigation in clinical trial NCT05555589 (Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2).

  5. Drug

    RD13-02

    go.drugbank.com/drugs/DB27110
    Investigational

    RD13-02 is under investigation in clinical trial NCT05923541 (RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies).

  6. Drug

    2-Hydroxylpropyl-beta-cyclodextrin

    go.drugbank.com/drugs/DB15146
    Investigational

    Adrabetadex is under investigation in clinical trial NCT03887533 (Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1).

  7. Drug

    Pimagedine

    go.drugbank.com/drugs/DB05383
    Investigational

    Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease.

  8. Drug

    Nemonoxacin

    go.drugbank.com/drugs/DB06600
    Investigational

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  9. Drug

    TA-CIN

    go.drugbank.com/drugs/DB05809
    Investigational

    TA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.

  10. Drug

    VPM4001

    go.drugbank.com/drugs/DB05089
    Experimental

    VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma.